SCHEMBL22874541

SCHEMBL22874541

COc1cccc(COc2ccc(NC(C)(C)C)cc2)c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 8/20 0.62
▸ BCHE P06276 2/20 0.51
▸ IDO1 P14902 2/20 0.50
▸ AGXT P21549 2/20 0.50
▸ FFAR1 O14842 1/20 0.49
▸ RAB9A P51151 3/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ MRGPRX4 Q96LA9 2/20 0.48
▸ TP53 P04637 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ NFKB2 Q00653 1/20 0.48
▸ RELA Q04206 1/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21340758 0.84 MAOB (0.68) MAOBBCHEIDO1AGXTRAB9A
SCHEMBL14547318 0.83 MAOB (0.81) MAOBBCHEIDO1AGXTRAB9A
SCHEMBL22874577 0.83 MAOB (0.60) MAOBKDM4EALDH1A1LMNA
SCHEMBL22967634 0.83 MAOB (0.60) MAOBFFAR1PKM
SCHEMBL12347496 0.82 AR (0.60) MAOBBCHERAB9ANPC1SMN1; SMN2
SCHEMBL13439679 0.81 MAOB (0.68) MAOBBCHEIDO1AGXTRAB9A
SCHEMBL22874619 0.81 MAOB (0.64) MAOBIDO1FFAR1ALDH1A1MRGPRX4
SCHEMBL22967629 0.81 FFAR1 (0.53) MAOBFFAR1MRGPRX4
SCHEMBL4412216 0.80 MAOB (0.77) MAOBBCHEIDO1AGXTFFAR1
SCHEMBL22874546 0.80 MAOB (0.62) MAOBBCHEIDO1AGXTFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-10 — — US disclosed
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2021-02-11 — — US disclosed
EP-3760633-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-01-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof WNK1, WNK2, WNK3 MAOB 975/4885BCHE 2153/4885IDO1 839/4885
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF WNK1, WNK2, WNK3 MAOB 975/4885BCHE 2153/4885IDO1 839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback